Defining the needs for next generation assays for tuberculosis

Journal of Infectious Diseases

Volumn 211, Issue , 2015, Pages S29-S38

  Denkinger, Claudia M ^a,b   Kik, Sandra V ^c   Cirillo, Daniela Maria ^d   Casenghi, Martina ^e   Shinnick, Thomas ^f   Weyer, Karin ^g   Gilpin, Chris ^d   Boehme, Catharina C ^a   Schito, Marco ^h   Kimerling, Michael ⁱ   Pai, Madhukar ^c  

^a FIND   (Switzerland)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

ⁱ BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Diagnosis; Point of care; Prioritization; Target product profiles; Tuberculosis

Indexed keywords

RIFAMPICIN; BIOLOGICAL MARKER;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CONSENSUS DEVELOPMENT; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; EMERGENCY HEALTH SERVICE; HEALTH AUXILIARY; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; MICROSCOPY; NEEDS ASSESSMENT; PRIORITY JOURNAL; RAPID TEST; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; SPUTUM SMEAR; TUBERCULOSIS; DIAGNOSTIC TEST; ECONOMICS; HEALTH CARE PLANNING; MEDICAL RESEARCH; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR DIAGNOSIS; PROCEDURES; SPUTUM; TRENDS;

BIOMARKERS; BIOMEDICAL RESEARCH; DIAGNOSTIC TESTS, ROUTINE; HEALTH PRIORITIES; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; SPUTUM; TUBERCULOSIS;

EID: 84929994231     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu821     Document Type: Article

References (47)

1. World Health Organization. Global Tuberculosis Control: WHO report 2014. Geneva: World Health Organization, 2014.
2. Dowdy DW, Houben R, Cohen T, et al. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. Int J Tuberc Lung Dis 2014; 18:1012-8.
3. Kik SV, Denkinger CM, Casenghi M, Vadnais C, Pai M. Tuberculosis diagnostics: which target product profiles should be prioritised? Eur Respir J 2014; 44:537-40.
4. World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva: World Health Organization, 2014.
5. van't Hoog A, Cobelens FG, Vassall A, et al. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: a decision analysis. PLOS One 2013; 8:e82786.
6. Graham SM, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012; 205(suppl 2):S199-208.
7. Batz H-G, Cooke GS, Reid SD. Towards lab-free tuberculosis diagnosis: Treatment Action Group, Stop TB Partnership, Imperial College London. London: MÉDECINS SANS FRONTIÈRES, 2011.
8. Denkinger CM, Kik SV, Pai M. Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries. Expert Rev Mol Diagn 2013; 13:763-7.
9. Wells WA, Boehme CC, Cobelens FG, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013; 13:449-58.
10. Pai M, Denkinger CM, Kik SV, et al. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clin Microbiol Rev 2014; 27:3-20.
11. Wallis RS, Kim P, Cole S, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis 2013; 13:362-72.
12. Kik SV, Denkinger CM, Chedore P, Pai M. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J 2014; 43:1793-6.
13. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; 1:CD009593.
14. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One 2008; 3:e1536.
15. World Health Organization. WHO monitoring of Xpert MTB/RIF rollout. 2014.
16. Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME. Which new diagnostics for tuberculosis, and when? J Infect Dis 2012; 205(suppl 2):S191-8.
17. Denkinger CM, Pai M. Point-of-care tuberculosis diagnosis: are we there yet? Lancet Infect Dis 2012; 12:169-70.
18. Denkinger CM, Nicolau I, Ramsay A, Chedore P, Pai M. Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? Eur Respir J 2013; 42:544-7.
19. Raizada N, Sachdeva KS, Sreenivas A, et al. Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in India. PLoS One 2014; 9:e89301.
20. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary- care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014; 383:424-35.
21. UNITAID. Tuberculosis: Diagnostic Technology and Market Landscape. Geneva: World Health Organization, 2014.
22. Sun AY, Pai M, Salje H, Satyanarayana S, Deo S, Dowdy DW. Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in Southeast Asia. Am J Epidemiol 2013; 178:1740-9.
23. World Health Organization. Global tuberculosis report 2011. Geneva 2011:1-246.
24. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis 2014; 14:527-32.
25. Claassens MM, du Toit E, Dunbar R, et al. Tuberculosis patients in primary care do not start treatment. What role do health system delays play? Int J Tuberc Lung Dis 2013; 17:603-7.
26. Sreeramareddy CT, Kishore PV, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis 2009; 9:91.
27. Colla M. Cepheid presentation on Xpert MTB/RIF failure rates. In: Geneva: Global Laboratory Initiative.
28. Banoo S, Bell D, Bossuyt P, et al. Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol 2010; 8:S17-29.
29. Dowdy DW, Lotia I, Azman AS, Creswell J, Sahu S, Khan AJ. Population- level impact of active tuberculosis case finding in an Asian megacity. PLoS One 2013; 8:e77517.
30. Denkinger CM, Kampmann B, Ahmed S, Dowdy DW. Modeling the impact of novel diagnostic tests on pediatric and extrapulmonary tuberculosis. BMC Infect Dis 2014; 14:477.
31. Sohn H, Aero AD, Menzies D, et al. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis 2014; 58:970-6.
32. Peter JG, Theron G, Singh N, Singh A, Dheda K. Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings. Eur Respir J 2014; 43:185-94.
33. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J 2014; 44:435-46.
34. Girosi F, Olmsted SS, Keeler E, et al. Developing and interpreting models to improve diagnostics in developing countries. Nature 2006; 444(suppl 1):3-8.
35. World Health Organization. A systematic review of the sensitivity and specificity of symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative persons and persons with unknown HIV status, 2013.
36. Dowdy DW, Hoog AV, Shah M, Cobelens F. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis. Int J Tuberc Lung Dis 2014; 18:647-54.
37. Bates M, O'Grady J, Maeurer M, et al. Assessment of the Xpert MTB/ RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis 2013; 13:36-42.
38. Zar HJ, Workman L, Isaacs W, et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis 2012; 55:1088-95.
39. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005; 365:130-4.
40. Marais BJ, Pai M. Specimen collection methods in the diagnosis of childhood tuberculosis. Indian J Med Microbiol 2006; 24: 249-51.
41. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007; 11:1-314.
42. Cuevas LE, Browning R, Bossuyt P, et al. Evaluation of tuberculosis diagnostics in children: 2. Methodological issues for conducting and reporting research evaluations of tuberculosis diagnostics for intrathoracic tuberculosis in children. Consensus from an expert panel. J Infect Dis 2012; 205(suppl 2):S209-15.
43. Pai M. TB diagnostics: FAQs by test developers. IJTLD 2013; 17:1-2.
44. WHO/TDR/FIND. Diagnostics for tuberculosis. Global demand and market potential. Geneva: World Health Organization, 2006: 1-203.
45. Consortium TBDMA. Market assessment of tuberculosis diagnostics in Brazil in 2012. PLoS One 2014; 9:e104105.
46. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J 2013; 42:708-20.
47. World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015, 2014.